The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.
May 4th 2024
Authors discuss the merits of using a pair of immunotherapy treatments aimed at separate targets.
Axi-Cel Yields High Responses in R/R High-Risk Large B-Cell Lymphoma
September 29th 2023Findings from the phase 2 ALYCANTE trial support axicabtagene ciloleucel as a second-line treatment for patients with relapsed/refractory (R/R) large B-cell lymphoma who are ineligible to undergo a transplant.
Read More
First-Line Sacituzumab Govitecan Plus Pembrolizumab Shows Promising Early Activity in NSCLC
September 20th 2023In a preliminary analysis of the phase 2 EVOKE-02 trial, the investigational combination regimen showed an objective response rate of 56% in previously untreated patients with metastatic non–small cell lung cancer (NSCLC).
Read More
Long-Term Data Show Consistent OS Benefit With Nivolumab Plus Ipilimumab in mNSCLC
September 13th 2023The combination demonstrated durable survival benefits among patients with metastatic non–small cell lung cancer (mNSCLC) regardless of PD-L1 expression levels at a minimum follow-up of more than 6 years.
Read More
Second-Line Axi-Cel Produces Complete Metabolic Responses in Transplant-Ineligible LBCL
August 24th 2023Second-line treatment with axicabtagene ciloleucel (axi-cel) led to an investigator-assessed, 3-month complete metabolic response rate of 71.0% in patients with large B-cell lymphoma (LBCL) who were ineligible for autologous stem cell transplant.
Read More
Group Highlights Barriers to CAR T-Cell Referral for DLBCL
July 29th 2023The researchers emphasized the importance of early referral for chimeric antigen receptor (CAR) T-cell treatment, as patients eligible for the treatment are often in very late stages of disease, and mitigating delays in care has the potential to improve response rates by more than 10%.
Read More
Overall Survival in Advanced NSCLC Unaffected by Immunotherapy Duration Beyond 2 Years
July 29th 2023Researchers seeking answers regarding the most beneficial duration of immune checkpoint inhibitor–based therapy for non–small cell lung cancer (NSCLC) found no significant impact of indefinite-duration treatment on patient survival.
Read More
Pembrolizumab Sustains Efficacy at 5 Years in First-Line, PD-L1+, Advanced NSCLC
July 15th 2023Findings from the 5-year follow-up analysis of the phase 3 KEYNOTE-042 study continue to support frontline pembrolizumab as standard of care for PD-L1-positive, locally advanced/metastatic non–small cell lung cancer (NSCLC).
Read More
At 5 Years, Data Affirm Durability of Axi-Cel Response in Refractory LBCL
June 22nd 2023Considering the depth and durability of responses with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL), the investigators added that CAR T cells should no longer be seen as a therapy only for heavily pretreated patients, but also as an option for earlier lines of therapy.
Read More
Study Finds Axi-Cel Benefits Older Patients With Relapsed or Refractory LBCL
June 17th 2023The findings, which suggest that axicabtagene ciloleucel (axi-cel) may be a good option for a patient group often deemed ineligible for other curative-intent therapy, come from a planned subgroup analysis from the ZUMA-7 trial.
Read More
Axi-Cel Shows Favorable Safety, Efficacy in Real-World Study of Early FL Outcomes
June 9th 2023The autologous CAR T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated effectiveness and safety consistent with the ZUMA-5 trial when used in real-world settings to treat a broader population of patients with follicular lymphoma (FL).
Read More
Addressing Unmet Need: Could Children With Low-Grade Gliomas Have a New Treatment in Tovorafenib?
May 6th 2023For Brain Cancer Awareness Month, AJMC shares an interview with Day One Biopharmaceuticals CEO Jeremy Bender, PhD, MBA. Bender discussed the company's lead agent, tovorafenib, which has shown promise in treatment of pediatric low-grade glioma.
Read More
Patients With Advanced Cancer With High TMB Show Favorable Outcomes on ICIs
May 5th 2023A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had low-TMB cancers.
Read More
Despite Potential Benefits, Barriers to CAR T-Cell Therapy for DLBCL Persist
April 13th 2023Chimeric antigen receptor (CAR) T-cell therapies have shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but barriers to referral may obstruct patient access to them.
Read More